Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)Christian F. Singer, Michael Gnant, Christoph Tinchon et al.|European Journal of Cancer|2020Cited by 52
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trialPeter Dubsky, Martin Filipits, Christian F. Singer et al.|European Journal of Cancer|2020Cited by 52
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34Rupert Bartsch, Christian F. Singer, Georg Pfeiler et al.|British Journal of Cancer|2021Cited by 16
Ki67 to predict RCB0/I after neoadjuvant chemotherapy and endocrine therapy in HER2- breast cancer patients from ABCSG 34.Christian F. Singer, Michael Gnant, Margaretha Rudas et al.|Journal of Clinical Oncology|2018Cited by 2
Supplementary Figure from Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor ResponseQing Zhou, Ellen Heitzer, Simon Peter Gampenrieder et al.|Unknown|2023Cited by 0